

6<sup>th</sup>

International Conference on

## Thrombosis and Hemostasis Issues in Cancer

Bergamo, Italy April 20-22, 2012

6th ICTHIC Preliminary Scientific Program**Friday, April 20th, 2012****2.15-4.15 pm Plenary Session 1: Epidemiology and risk factors of venous thromboembolism**

Chairs: H.A. Liebman (USA), I. Pabinger (Austria)

- Predictive potential of hemostatic biomarkers  
C. Ay (Austria)
- Update on thrombotic risk stratification  
A. Khorana (USA)
- Unsuspected PE in cancer patients  
M. Monreal (Spain)
- Cancer in pregnancy  
B. Brenner (Israel)
- Oral Communications (from abstracts)

**4.45-6.45 pm Plenary Session 2: Genomics and proteomics of the hemostatic system in cancer**

Chairs: M.-M. Samama (France), M. Cattaneo (Italy)

- Genetic pathways linking hemostasis and cancer  
J. Rak (Canada)
- Platelet CLEC-2 in lymphangiogenesis and cancer metastasis  
S.P. Watson (UK)
- The platelet proteome  
W.F. Bahou (USA)
- Akt and Ras Pathways and modulation of TF expression in glioblastoma  
D. Brat (USA)
- Oral Communications (from abstracts)

**7.30 pm Plenary Lecture: 2nd Simon Karparkin Memorial Lecture**

Introduction F. Rickles (USA)

- Hemostasis, innate immunity and malignancy  
J. Degen (USA)

**Saturday, April 21st, 2012****8.30-10.30 am Plenary Session 3 : Bleeding Complications in cancer patients**

Chairs: C. Velati (Italy), TBA

- Side effects of anti-angiogenic drugs  
F. Rodeghiero (Italy)
- Diagnosis and treatment of disseminated intravascular coagulation  
C.-H. Toh (UK)
- Transfusion issues in the cancer patient  
A.B. Federici (Italy)
- Acquired hemophilias in cancer  
N.S. Key (USA)
- Oral Communications (from abstracts)

**11.00 am - 1.00 pm Plenary Session 4: Hemostasis, Thrombosis and Cancer Progression**

Chairs: M.B. Donati (Italy), TBA

- The respective roles of TF isoforms in cancer  
H. Versteeg (Netherlands)
- Heparanase procoagulant activity  
Y. Nadir (Israel)
- Protein C and cancer  
C.A. Spek (Netherlands)
- Accounting for death as a competing risk in cancer VTE studies  
J. Zwicker (USA)
- Oral Communications (from abstracts)



2.30-4.30 pm **Plenary Session 5: Thrombosis and Hemorrhage in Hematological Malignancies**

*Chairs: T. Barbui (Italy), P.M. Sandset (Norway)*

- Risk and management of thrombosis in multiple myeloma  
F.W. Leebeek (*Netherlands*)
  - The role of JAK-2 mutations in thrombosis  
A.Rambaldi (*Italy*)
  - Splanchnic vein thrombosis: New risk factors and management  
W. Ageno (*Italy*)
  - Heparin-induced thrombocytopenia in cancer  
TBA
- Oral Communications (from abstracts)

5.00-7.00 pm **Plenary Session 6: Anticoagulants and Cancer**

*Chairs: S. Schulman (Canada), H. Buller (Netherlands)*

- New and old anticoagulants in cancer  
G. Agnelli (*Italy*)
  - Guidelines for antithrombotics in cancer patients  
D. Farge-Bancel (*France*)
  - Measurement of new oral anticoagulants  
J. Harenberg (*Germany*)
  - LMWH and survival in lung cancer  
S. Noble (*UK*)
- Oral Communications (from abstracts)

**Sunday, April 22nd, 2012**

8.30 - 10.30 am **Plenary Session 7: Platelets and vascular endothelium**

*Chairs: C.W. Francis (USA), H. ten Cate (Netherlands)*

- The role of thrombomodulin in tumor growth and metastasis  
N. Horowitz (*Israel*)
  - Endothelial cell activation markers in cancer  
A.D. Blann (*UK*)
  - Novel functions of tissue factor in thrombosis and in cancer  
W. Ruf (*USA*)
  - Microparticles and Angiogenesis  
Falanga A. /Marchetti M. (*Italy*)
- Oral Communications (from abstracts)

11.00 am - 1.00 pm **Plenary Session 8: Prevention and Treatment of Thrombosis**

*Chairs: M.N. Levine (Canada), P. Prandoni (Italy)*

- Thromboprophylaxis in the cancer surgical patient  
A.K. Kakkar (*UK*)
  - Thromboprophylaxis in the cancer medical patient  
A.T. Cohen (*UK*)
  - Treatment of established thrombotic events  
A.Y. Lee (*Canada*)
  - Overview of thrombosis and cancer survival  
N. Kuderer (*USA*)
- Oral Communications (from abstracts)

2.30-4.30 pm **Poster Sessions**